Influenza continues to cause major illness each year in the United States, leading to more than 35,000 deaths annually.

The results reinforce that Evaxion's pioneering AI platform, AI-Immunology™ accurately identifies and selects the most relevant vaccine targets COPENHAGEN, Denmark, April 17, 2026 - Evaxion A/S ...

EVX-05 is an off-the-shelf therapeutic glioblastoma (brain cancer) vaccine designed based on patient tumor samples. It targets novel conserved ...

Malaria remains one of the most pressing global health challenges, with Plasmodium falciparum and Plasmodium vivax causing the majority of morbidity and mortality. Immunological control of malaria ...

Intismeran Autogene, a vaccine that treats melanoma, a deadly type of skin cancer, has made headlines worldwide. Recently ...

Vermont Business Magazine Researchers at the University of Vermont's Vaccine Testing Center are seeking volunteers age 65 and older to participate in a Phase 3 clinical trial of an investigational ...

The global challenge posed by HIV-1 arises from its rapid genetic diversification, extensive glycan shielding of the envelope glycoprotein and its ability to establish latent reservoirs. Immunological ...

COPENHAGEN, Denmark, August 20, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business ...

Three-year data from phase 2 trial will provide additional insights into potentially enhanced treatment effects and durability of the EVX-01-induced immune response Data will also offer insight into ...

New phase 2 data from personalized cancer vaccine EVX-01 demonstrates a record-high rate of vaccine targets triggering a tumor-specific immune response The results reinforce that Evaxion’s pioneering ...